使用免疫检查点抑制剂治疗癌症患者心肌炎的风险

Chronicles of Oncology Pub Date : 2018-06-07 DOI:10.33582/2638-4248/1004

Matthew Kelling, Kansas City Missouri Usa Biosciences, M. Dimza, S. Dalia, Joplin Missouri Usa Biosciences

{"title":"使用免疫检查点抑制剂治疗癌症患者心肌炎的风险","authors":"Matthew Kelling, Kansas City Missouri Usa Biosciences, M. Dimza, S. Dalia, Joplin Missouri Usa Biosciences","doi":"10.33582/2638-4248/1004","DOIUrl":null,"url":null,"abstract":"Cite this article: Kelling M, Dimza M, Dalia S. Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors. Chronicles Oncol. 2018; 1: 1004. Matthew Kelling MS1; Michelle Dimza1; Samir Dalia MD2* 1Kansas City University of Medicine and Biosciences, Kansas City, Missouri, USA 2Adjunct Clinical Assistant Professor of Hematology/Oncology, Kansas City University of Medicine and Biosciences, Joplin, Missouri, USA","PeriodicalId":433633,"journal":{"name":"Chronicles of Oncology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors\",\"authors\":\"Matthew Kelling, Kansas City Missouri Usa Biosciences, M. Dimza, S. Dalia, Joplin Missouri Usa Biosciences\",\"doi\":\"10.33582/2638-4248/1004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cite this article: Kelling M, Dimza M, Dalia S. Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors. Chronicles Oncol. 2018; 1: 1004. Matthew Kelling MS1; Michelle Dimza1; Samir Dalia MD2* 1Kansas City University of Medicine and Biosciences, Kansas City, Missouri, USA 2Adjunct Clinical Assistant Professor of Hematology/Oncology, Kansas City University of Medicine and Biosciences, Joplin, Missouri, USA\",\"PeriodicalId\":433633,\"journal\":{\"name\":\"Chronicles of Oncology\",\"volume\":\"52 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chronicles of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33582/2638-4248/1004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronicles of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33582/2638-4248/1004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Kelling M, Dimza M, Dalia S.免疫检查点抑制剂治疗癌症患者心肌炎的风险。编年史，2018;1: 1004。马修·凯林MS1;米歇尔Dimza1;Samir Dalia MD2* 1Kansas City Medicine and Biosciences University, Kansas City, Missouri, USA 2 Kansas City Medicine and Biosciences University, Joplin, USA, Missouri，兼任血液学/肿瘤学临床助理教授

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors

Cite this article: Kelling M, Dimza M, Dalia S. Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors. Chronicles Oncol. 2018; 1: 1004. Matthew Kelling MS1; Michelle Dimza1; Samir Dalia MD2* 1Kansas City University of Medicine and Biosciences, Kansas City, Missouri, USA 2Adjunct Clinical Assistant Professor of Hematology/Oncology, Kansas City University of Medicine and Biosciences, Joplin, Missouri, USA

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Chronicles of Oncology

自引率

0.00%

发文量